DermTech (NASDAQ:DMTK) Earns Hold Rating from Lake Street Capital

Lake Street Capital reaffirmed their hold rating on shares of DermTech (NASDAQ:DMTK) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $0.63 target price on the stock.

DMTK has been the topic of a number of other research reports. BTIG Research reissued a neutral rating on shares of DermTech in a research report on Friday. Stephens reaffirmed an equal weight rating and issued a $1.50 price target on shares of DermTech in a report on Friday.

DermTech Stock Down 7.5 %

DMTK stock opened at $0.60 on Friday. The firm has a market capitalization of $20.62 million, a P/E ratio of -0.19 and a beta of 2.52. DermTech has a 52 week low of $0.59 and a 52 week high of $4.02. The company has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $1.22.

DermTech (NASDAQ:DMTK) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02). DermTech had a negative return on equity of 123.96% and a negative net margin of 659.57%. The firm had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $4.05 million. As a group, analysts anticipate that DermTech will post -2.26 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of DermTech by 100.0% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 120,000 shares of the company’s stock worth $210,000 after acquiring an additional 60,000 shares during the period. Savant Capital LLC acquired a new position in DermTech in the 4th quarter worth about $62,000. Finally, Quantum Private Wealth LLC raised its stake in shares of DermTech by 35.4% during the 4th quarter. Quantum Private Wealth LLC now owns 33,045 shares of the company’s stock worth $58,000 after buying an additional 8,634 shares during the period. 20.45% of the stock is owned by institutional investors and hedge funds.

About DermTech

DermTech, Inc, a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.